• George D. Demetri

• Graduated: Stanford Medical School • Residency: Univ. of Washington Hospitals

Internal Medicine• Fellowship: Dana Farber Cancer Institute,

Hematology & Oncology, Boston

• Board certification Internal Medicine 1986• Board certification Oncology 1989

• Professor of Medicine,Harvard Medical SchoolDirector, Center of Sarcoma and Bone Oncology, DFCIDirector of the Ludwig CenterSenior Vice President of Experimental Therapeutics

• PubMed 265 publications

Drug development in sarcoma

Imatinib Sunitinib Regorafenib Nilotinib Retaspymicin Ridaforolimus Trabectedin Tivantinib Efatutazone Conatumumab Everolimus CDK4 inhibitors Dasatinib

flagship of innovation in soft tissue sarcoma

George D. Demetri

• ‘Creative, high speed lab’• George and Jaap Verweij wrote the protocol for phase III for

imatinib in metastatic GIST (SWOG-033 and EORTC 62005) overnight from October 31 – November 1, 2000.

• This study marked the start of an intensified contact between US and EU sarcoma researchers.

• Start of very much improved collaboration between US and EORTC and for the setup of Worls´d SarcomaNetwork (WSN).

• Example of an international oriented researcher who will always seek collaboration

• Surplus

Now and here